Literature DB >> 18434340

Comment on: concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.

John M Nicholls, Laura M Aschenbrenner, James C Paulson, Erin R Campbell, Michael P Malakhov, David F Wurtman, Mang Yu, Fang Fang.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18434340      PMCID： PMC6281384          DOI： 10.1093/jac/dkn167

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  10 in total

1.  Bronchotracheal response in human influenza. Type A, Asian strain, as studied by light and electron microscopic examination of bronchoscopic biopsies.

Authors:  J J WALSH; L F DIETLEIN; F N LOW; G E BURCH; W J MOGABGAB
Journal:  Arch Intern Med       Date:  1961-09

2.  Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus.

Authors:  M C Plotkowski; E Puchelle; G Beck; J Jacquot; C Hannoun
Journal:  Am Rev Respir Dis       Date:  1986-11

3.  Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

Authors:  Michael P Malakhov; Laura M Aschenbrenner; Donald F Smee; Miles K Wandersee; Robert W Sidwell; Larisa V Gubareva; Vasiliy P Mishin; Frederick G Hayden; Do Hyong Kim; Alice Ing; Erin R Campbell; Mang Yu; Fang Fang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Influenza virus infection of desialylated cells.

Authors:  S J Stray; R D Cummings; G M Air
Journal:  Glycobiology       Date:  2000-07       Impact factor: 4.313

5.  Influenza virus entry and infection require host cell N-linked glycoprotein.

Authors:  Victor C Chu; Gary R Whittaker
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-15       Impact factor: 11.205

Review 6.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Authors:  J J Skehel; D C Wiley
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

7.  Involvement of the platelet-activating factor receptor in host defense against Streptococcus pneumoniae during postinfluenza pneumonia.

Authors:  Koenraad F van der Sluijs; Leontine J R van Elden; Monique Nijhuis; Rob Schuurman; Sandrine Florquin; Takao Shimizu; Satoshi Ishii; Henk M Jansen; René Lutter; Tom van der Poll
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2005-08-12       Impact factor: 5.464

8.  DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

Authors:  Jessica A Belser; Xiuhua Lu; Kristy J Szretter; Xiaoping Jin; Laura M Aschenbrenner; Alice Lee; Stephen Hawley; Do Hyong Kim; Michael P Malakhov; Mang Yu; Fang Fang; Jacqueline M Katz
Journal:  J Infect Dis       Date:  2007-10-31       Impact factor: 5.226

Review 9.  Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza.

Authors:  Hong Zhang
Journal:  J Antimicrob Chemother       Date:  2008-01-31       Impact factor: 5.790

10.  Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin.

Authors:  Aarthi Chandrasekaran; Aravind Srinivasan; Rahul Raman; Karthik Viswanathan; S Raguram; Terrence M Tumpey; V Sasisekharan; Ram Sasisekharan
Journal:  Nat Biotechnol       Date:  2008-01-06       Impact factor: 54.908
  10 in total
  9 in total

1.  A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo.

Authors:  Anne Moscona; Matteo Porotto; Samantha Palmer; Caroline Tai; Lori Aschenbrenner; Gallen Triana-Baltzer; Qi-Xiang Li; David Wurtman; Stefan Niewiesk; Fang Fang
Journal:  J Infect Dis       Date:  2010-07-15       Impact factor: 5.226

2.  Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.

Authors:  Maria Hedlund; Laura M Aschenbrenner; Kellie Jensen; Jeffrey L Larson; Fang Fang
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

3.  DAS181 inhibits H5N1 influenza virus infection of human lung tissues.

Authors:  Renee W Y Chan; Michael C W Chan; Adam C N Wong; Rositsa Karamanska; Anne Dell; Stuart M Haslam; Alan D L Sihoe; W H Chui; Gallen Triana-Baltzer; Qixiang Li; J S Malik Peiris; Fang Fang; John M Nicholls
Journal:  Antimicrob Agents Chemother       Date:  2009-07-13       Impact factor: 5.191

4.  DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis.

Authors:  Gallen B Triana-Baltzer; Maria Babizki; Michael C W Chan; Adam C N Wong; Laura M Aschenbrenner; Erin R Campbell; Qi-Xiang Li; Renee W Y Chan; J S Malik Peiris; John M Nicholls; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2009-11-26       Impact factor: 5.790

Review 5.  Antiviral strategies against influenza virus: towards new therapeutic approaches.

Authors:  Arianna Loregian; Beatrice Mercorelli; Giulio Nannetti; Chiara Compagnin; Giorgio Palù
Journal:  Cell Mol Life Sci       Date:  2014-04-04       Impact factor: 9.261

6.  Antiviral strategies for pandemic and seasonal influenza.

Authors:  Maria Hedlund; Jeffrey L Larson; Fang Fang
Journal:  Viruses       Date:  2010-08-20       Impact factor: 5.818

7.  Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; John M Nicholls; Melissa B Pearce; Vasiliy P Mishin; Jessica A Belser; Li-Mei Chen; Renee W Y Chan; Michael C W Chan; Maria Hedlund; Jeffrey L Larson; Ronald B Moss; Jacqueline M Katz; Terrence M Tumpey; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

8.  Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.

Authors:  Gallen B Triana-Baltzer; Larisa V Gubareva; Alexander I Klimov; David F Wurtman; Ronald B Moss; Maria Hedlund; Jeffrey L Larson; Robert B Belshe; Fang Fang
Journal:  PLoS One       Date:  2009-11-06       Impact factor: 3.240

Review 9.  The use of sialidase therapy for respiratory viral infections.

Authors:  John M Nicholls; Ronald B Moss; Stuart M Haslam
Journal:  Antiviral Res       Date:  2013-04-17       Impact factor: 5.970
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.